Tag: psychedelics

Pilgrims Are Flocking to This Psychedelic Temple

UPSTATE NEW YORK has been the birthplace of many Great Awakenings. In the 1820s, religious fervor so swept the region it became known as “the burned-over district.” In the 1960s, Timothy Leary’s commune in Millbrook became ground control for the East Coast psychedelic movement. “By the time we got to Woodstock,” sang Joni Mitchell, “we were half a million strong.”

More than five decades after Woodstock, in Wappinger Falls, Alex Grey and his wife, Allyson Grey, are trying to use art to get back to the garden. Under the full June moon earlier this month, the Greys opened the bronze, 700-pound doors of Entheon, a temple-museum hybrid dedicated to advancing visionary art, and a message of ecological unity. 

“Humanity’s materialistic worldview must transition to a sacred view of oneness with the environment and cosmos,” Alex tells me after the celebration where soap heir David Bronner, who funded part of the museum, billowed about in his purple robes like a psychedelic Medici. It is a message Americans heard before — in the indigenous language of animacy, and in the prose of Alan Watts, who wrote that the individual is not, contrary to our common perception, a separate “ego inside a bag of skin,” but more like a wave coming out of the ocean. 

As psychedelics return from the outlaw regions of the culture, arriving alongside the climate crisis, the gospel of interconnectedness is spreading again, this time through the mycelial tendrils of the internet. Alex Grey, demure and snowy-haired at age 69, is not entirely sure why he has become such a popular progenitor, but he nevertheless has: On Instagram, he is one of the most famous living visual artists in the country, with 1.4 million followers — more than Jeff Koons and Yayoi Kusama combined. 

Keep reading

A Neurosurgeon Compares His Near-Death Experience With Smoking Psychedelic Toad Slime

Few neuroscientists can claim to have probed the outer limits of human consciousness to the same extent as Dr Eben Alexander. After contracting bacterial meningoencephalitis in 2008, the brain surgeon wrote a book describing his remarkable near-death experience (NDE) while in a coma. A decade later, he smoked the psychedelic venom of the Sonoran Desert toad, and has now provided a detailed comparison of the two life-changing events.

Introducing their interviewee, the authors of the new report explain that NDEs and psychedelic experiences often have “shared characteristics such as entering other worlds, meeting menacing or benevolent entities, experiencing synesthesia, perinatal regression, and lucid dreamlike properties.” However, they go on to say that no studies have ever compared the experience of dying with the effects of 5-MeO-DMT, the main psychoactive component in the secretions of certain hallucinogenic toads.

Finding a subject familiar with both experiences is no easy feat, and it’s unlikely there are many out there other than Alexander. Recording the neurosurgeon’s testimony, therefore, provided the researchers with a rare opportunity to analyze the “high level of comparability” between NDEs and smoking 5-MeO-DMT.

In particular, the authors say that both experiences are characterized by a sense of “ego dissolution” as well as “transcendence of time and space.” Regarding the former, Alexander explains that during his NDE, he found himself “in a position similar to that of someone with partial but beneficial amnesia. That is, a person who has forgotten some key aspect about him or herself, but who benefits from having forgotten it.”

Keep reading

FDA creates path for psychedelic drug trials

Federal regulators are laying out guidance for psychedelic drug trials for the first time, in a move that could encourage the mainstreaming of substances like magic mushrooms and LSD as behavioral health treatments.

Why it matters: Psychedelics are turning into a multi-billion industry and gaining widespread acceptance after decades of concerns about recreational use of the products — and the high risk for misuse. But research to date has largely been backed by private sponsors.

Driving the news: The Food and Drug Administration on Friday released first-ever draft guidance outlining considerations — including trial conduct, data collection and subject safety — for researchers looking into psychedelic treatments for a variety of conditions, including PTSD, depression and anxiety.

  • The agency filed the 14-page document two days after a bipartisan coalition in Congress led by Rep. Dan Crenshaw (R-Texas) introduced legislation directing the issuance of clinical trial guidelines.
  • It also came as 10,000 attendees and hundreds of exhibitors converged on Denver for what was billed as the “largest psychedelic conference in history,” with guests ranging from New York Jets quarterback Aaron Rodgers to National Institute of Mental Health director Joshua Gordon.

Keep reading

Ancient Egyptian followers of a deity called Bes may have used hallucinogens

An ancient Egyptian vase in the shape of the deity Bes showed traces of chemical plant compounds known to produce hallucinations, according to a recent preprint posted to Research Square. The authors suggest that members of the cult of Bes may have consumed a special cocktail containing the compounds to induce altered states of consciousness.

There is ample evidence that humans in many cultures throughout history used various hallucinogenic substances in religious ceremonies or shamanic rituals. That includes not just ancient Egypt but also ancient Greek, Vedic, Maya, Inca, and Aztec cultures. The Urarina people who live in the Peruvian Amazon Basin still use a psychoactive brew called ayahuasca in their rituals, and Westerners seeking their own brand of enlightenment have also been known to participate.

Lacing the beer served at their feasts with hallucinogens may have helped an ancient Peruvian people known as the Wari forge political alliances and expand their empire, according to a 2022 study. As previously reported, the use of hallucinogens, particularly a substance derived from the seeds of the vilca tree, was common in the region during the so-called Middle Horizon period, when the Wari empire thrived.

Keep reading

Psychedelic drugs like LSD could enhance the effects of brain simulation

New research provides evidence that LSD alters the effects of brain stimulation and produces different and potentially larger changes in brain activity. The preliminary findings suggest that psychedelic drugs and brain stimulation may have a synergistic effect that could be used in innovative ways for treating various conditions. The proof-of-concept study has been published in the journal Psychedelic Medicine.

Psychedelic-assisted psychotherapy has shown promising potential as a therapeutic approach for various mental health conditions. This treatment combines the use of psychedelic substances, such as psilocybin or LSD, with psychotherapy sessions to enhance the therapeutic process.

The psychedelic substances used in this type of therapy are known to induce altered states of consciousness, leading to profound experiences that can have therapeutic benefits. These substances are thought to work by affecting brain receptors, particularly the serotonin 2A receptor, which influences perception, mood, and cognition.

These drugs have also been found to enhance neural plasticity, which refers to the brain’s ability to reorganize and form new connections. This may contribute to their long-term therapeutic effects. It is believed that combining psychedelic drugs with therapies like psychotherapy or brain stimulation could help direct these neuroplastic changes and lead to lasting behavioral changes.

“Current treatments like transcranial magnetic stimulation (TMS) have a large potential to help people with a variety of psychiatry disorders, however, these neuromodulatory treatments tend to have relatively short-lived effects,” explained study author Lucas Dwiel, a postdoctoral fellow at The Doucette Lab at the Geisel School of Medicine at Dartmouth. “So if we could prolong the effects of these treatments by first using drugs like LSD to make the brain more malleable or susceptible to change, we could help a large number of patients achieve their therapeutic goals.”

The researchers conducted experiments using rats to eliminate the biases inherent in human studies. The study focused on the effects of LSD and involved two main components: measuring brain activity changes after LSD administration and assessing the effects of brain stimulation combined with LSD.

Keep reading

Healing brain trauma with psychedelics

Ian McCall is a former professional Mixed Martial Arts (MMA) fighter who suffered from symptoms of traumatic brain injuries. After retirement, McCall experienced confusion, anger issues, depression, addiction and suicidal ideation. He tried brain stimulation therapy, but that did not work. So, he turned to a less traditional form of therapy: psilocybin mushrooms.

“I am a very loving, happy person, and I wasn’t for a large portion of my life. Because I was just tortured. I was tortured, and then I was confused, and I was addicted, and I was just crazy for a long time,” McCall said.

Psilocybin mushrooms, also known as magic mushrooms or shrooms, are naturally occurring psychedelics that can affect all senses. They can alter a person’s way of thinking and can cause hallucinations.

“The most important thing to know is that if you take psilocybin or LSD, they’re incredibly safe from a physiological standpoint. You can’t really overdose on them,” Dr. Daniel F. Kelly, a practicing neurosurgeon in Santa Monica said. “They don’t create an addictive behavior like say opiates or alcohol do or nicotine. And in fact, as you probably know, they’re used to break addiction.”

Keep reading

Hallucinogen use is on the rise among young adults

A significant upsurge in the usage of non-LSD hallucinogens among young adults in the United States is causing concern among researchers. An insightful study conducted by the University of Michigan and Columbia University reveals that in the period between 2018 and 2021, the use of these drugs by individuals aged 19 to 30 almost doubled.

Back in 2018, it was found that 3.4% of young adults reported having used non-LSD hallucinogens in the past year. This figure spiked to 6.6% in 2021. 

Sudden surge is surprising

While this prevalence remains relatively low compared to substance usage like alcohol and cannabis, this sudden surge over a mere three years presents potential public health worries.

“The increase in non-LSD hallucinogen use occurred while LSD use remained stable at around 4% in 2018 and 2021,” stated Megan Patrick, a research professor in the Survey Research Center at U-M’s Institute for Social Research. 

Patrick, who is a co-author of the study, emphasized that the leap in prevalence is substantial and raises critical health-related concerns.

How the study was conducted

This noteworthy information was uncovered as a part of the Monitoring the Future study, funded by the National Institute on Drug Abuse, and the results were published in the journal Addiction. 

The study, involving a longitudinal follow-up of 12th-grade students transitioning into adulthood, focused primarily on substance use and health.

In addition to the overall increase in hallucinogen usage, the research team discovered that the consumption of these substances was notably higher among males compared to females. 

Additionally, white young adults reported higher usage rates than Black young adults, and those whose parents possessed a college education, indicating a higher socioeconomic status, were also found to use these substances more frequently.

While the reasons behind the usage of these drugs, whether recreational or therapeutic, were not identified in the study, previous research has shown a link between nonmedical hallucinogen use and an increased risk of substance use disorders, self-harm, injury, and anxiety.

“With increased visibility for medical and therapeutic use, potentially comes diversion and unregulated product availability, as well as a lack of understanding among the public of potential risks,” explained Katherine Keyes, a professor of epidemiology at Columbia Mailman School and the lead author of the study.

Keep reading

These ‘Psychedelic Cryptography’ Videos Have Hidden Messages Designed to Be Seen While Tripping

A new competition focused on “Psychedelic Cryptography” has awarded cash prizes to artists who made videos encoded with hidden messages that can be most easily deciphered by a person who is tripping on psychedelic substances, such as LSD, ayahuasca, or psilocybin mushrooms.

Qualia Research Institute (QRI), a California-based nonprofit group that researches consciousness with backing from tech investors and experts, announced the winners of its Psychedelic Cryptography (PsyCrypto) contest last week. The goal of the exercise was “to create encodings of sensory information that are only meaningful when experienced on psychedelics in order to show the specific information-processing advantages of those states,” according to the original contest page, which was posted in March.

Artist Raimonds Jermaks clinched the first and second place prizes in the contest for videos entitled “Can You See Us?” and “ We Are Here. Let’s Talk.” The third prize went to Rūdolfs Balcers for the video “The Key.” The contest entries were judged by members of QRI’s international phenomenologist network, and evaluated based on their effectiveness, specificity, and aesthetic value.

The winning videos play on the common psychedelic experience of seeing radiant “tracers,” which are trails of colors and afterimages that linger in the visual field. The winning artists used this effect to write out tracer-based messages that are incomprehensible to a sober person, but that can be understood while tripping.  

Keep reading

New Study Analyzes Efficacy of Psilocybin as Treatment for Alcohol Use Disorder

A recent study published in the journal Psychology of Addictive Behaviors by the American Psychological Association on June 5 has found that psilocybin can be an effective treatment for people with alcohol addiction.

Officially entitled “Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis,” the study was conducted by researchers from New York University and University of California, San Francisco, as well as a psychedelic integration and psychedelic-assisted therapy business called Fluence.

The study objective was to “delineate psychological mechanisms of change” for those who suffer from alcohol use disorders (referred to as AUDs). All participants were engaged in interviews about their experiences, and asked questions about their alcohol use before and after the study. They were also asked about their coping patterns when enduring “strong emotions, stress, and cravings for alcohol.”

According to the study results, researchers examined how psilocybin helped them overcome various stressors. “Participants reported that the psilocybin treatment helped them process emotions related to painful past events and helped promote states of self-compassion, self-awareness, and feelings of interconnectedness,” researchers stated. “The acute states during the psilocybin sessions were described as laying the foundation for developing more self-compassionate regulation of negative affect. Participants also described newfound feelings of belonging and an improved quality of relationships following the treatment.”

Through this evidence, they explained that psilocybin “increases the malleability of self-related processing, and diminishes shame-based and self-critical thought patterns while improving affect regulation and reducing alcohol cravings,” the authors concluded. “These findings suggest that psychosocial treatments that integrate self-compassion training with psychedelic therapy may serve as a useful tool for enhancing psychological outcomes in the treatment of AUD.”

Keep reading

Magic mushrooms go mainstream in Colorado

Fungi are ready for their close-up.

Driving the news: After Coloradans voted to legalize psilocybin in 2022, “magic mushrooms” are now becoming more mainstream, with a first-of-its-kind study and a national psychedelic conference on the horizon.

State of play: The University of Colorado Anschutz Medical Campus in Aurora this month announced it would launch the first modern-era psilocybin clinical trial for depression this fall.

Details: The hospital is working with the Food and Drug Administration on the study, though the federal government classifies psilocybin mushrooms as a Schedule 1 narcotic.

  • It’s grouped with the most serious category of illicit drugs, including heroin and cocaine.

The intrigue: Gov. Jared Polis last week signed a bill implementing Proposition 122, which allows people 21 and older to grow and share magic mushrooms.

  • The bill also creates a regulated therapy system for medicinal use — establishing “healing centers” for people to use psilocybin under supervision — and removes criminal penalties for personal possession.

Keep reading